Dencatistat - Step Pharma
Alternative Names: CTPS1 inhibitor - Step Pharma; STP 938Latest Information Update: 06 Jun 2025
At a glance
- Originator Step Pharma
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Cytidine triphosphate synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II B-cell lymphoma; T-cell lymphoma
- Phase I Solid tumours
- Preclinical Graft-versus-host disease; Inflammation; Rheumatoid arthritis
Most Recent Events
- 22 May 2025 Dencatistat receives Orphan Drug status for T-cell lymphoma in USA
- 22 Jan 2025 Step Pharma plans a phase I trial for Essential thrombocythaemia (Treatment resistant) in the United Kingdom (PO) in first half of 2025 (NCT06786234)
- 02 Aug 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease) in USA (PO) (NCT06297525)